Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676198 | 0.89 | ACHE (0.38) | MEN1KMT2ABCHEACHELMNA | |
| SCHEMBL6677381 | 0.86 | APP (0.48) | MEN1KMT2ABCHEACHETSHR | |
| SCHEMBL6674324 | 0.83 | PIK3CA (0.48) | TSHRLMNAMKNK1RAB9ABACE1 | |
| SCHEMBL6675831 | 0.83 | GRK6 (0.43) | MEN1KMT2ABCHEACHETSHR | |
| SCHEMBL6674061 | 0.83 | MEN1 (0.43) | MEN1KMT2ABCHEACHETSHR | |
| SCHEMBL6679149 | 0.81 | TSHR (0.55) | MEN1KMT2ABCHEACHETSHR | |
| SCHEMBL2777052 | 0.80 | ALDH1A1 (0.52) | MEN1KMT2ABCHEACHELMNA | |
| SCHEMBL2250349 | 0.79 | USP2 (0.42) | MEN1KMT2ABCHEACHETSHR | |
| SCHEMBL2776923 | 0.78 | TRPC5 (0.46) | KMT2ATSHRGRK6LMNARAB9A | |
| SCHEMBL6674860 | 0.78 | PIK3CA (0.48) | TSHRLMNAMKNK1RAB9ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | MEN1 2339/4885KMT2A 853/4885BCHE 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.